4015 Stock Overview
Manufactures and markets pharmaceutical products in the Kingdom of Saudi Arabia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Jamjoom Pharmaceuticals Factory Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ر.س151.80 |
| 52 Week High | ر.س202.40 |
| 52 Week Low | ر.س124.80 |
| Beta | 0 |
| 1 Month Change | -4.53% |
| 3 Month Change | -2.82% |
| 1 Year Change | 15.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 94.62% |
Recent News & Updates
Earnings Miss: Jamjoom Pharmaceuticals Factory Company Missed EPS By 5.1% And Analysts Are Revising Their Forecasts
Mar 08
Jamjoom Pharmaceuticals Factory Company's (TADAWUL:4015) Business Is Yet to Catch Up With Its Share Price
Dec 17Recent updates
Earnings Miss: Jamjoom Pharmaceuticals Factory Company Missed EPS By 5.1% And Analysts Are Revising Their Forecasts
Mar 08Jamjoom Pharmaceuticals Factory Company's (TADAWUL:4015) Business Is Yet to Catch Up With Its Share Price
Dec 17Getting In Cheap On Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) Is Unlikely
Apr 30Shareholder Returns
| 4015 | SA Pharmaceuticals | SA Market | |
|---|---|---|---|
| 7D | 6.0% | -4.9% | -1.2% |
| 1Y | 15.0% | 0.7% | -12.7% |
Return vs Industry: 4015 exceeded the SA Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: 4015 exceeded the SA Market which returned -12.7% over the past year.
Price Volatility
| 4015 volatility | |
|---|---|
| 4015 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in SA Market | 7.4% |
| 10% least volatile stocks in SA Market | 3.1% |
Stable Share Price: 4015 has not had significant price volatility in the past 3 months compared to the SA market.
Volatility Over Time: 4015's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Tarek Youssef Hosni | www.jamjoompharma.com |
Jamjoom Pharmaceuticals Factory Company manufactures and markets pharmaceutical products in the Kingdom of Saudi Arabia and internationally. The company offers products human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer, and acidity, as well as various skin infections, cancer diseases, eye drops and ointments, and cosmeceuticals. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdom of Saudi Arabia.
Jamjoom Pharmaceuticals Factory Company Fundamentals Summary
| 4015 fundamental statistics | |
|---|---|
| Market cap | ر.س10.43b |
| Earnings (TTM) | ر.س356.52m |
| Revenue (TTM) | ر.س1.32b |
29.8x
P/E Ratio8.1x
P/S RatioIs 4015 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4015 income statement (TTM) | |
|---|---|
| Revenue | ر.س1.32b |
| Cost of Revenue | ر.س500.31m |
| Gross Profit | ر.س818.17m |
| Other Expenses | ر.س461.64m |
| Earnings | ر.س356.52m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.09 |
| Gross Margin | 62.05% |
| Net Profit Margin | 27.04% |
| Debt/Equity Ratio | 0% |
How did 4015 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield60%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 18:41 |
| End of Day Share Price | 2025/04/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jamjoom Pharmaceuticals Factory Company is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Appissa | Al Rajhi Capital |
| null null | J.P. Morgan |
| Tarek Sleiman | J.P. Morgan |